ArticleJournal of medical biochemistry2026
Serum inflammatory markers nt-probnp, hs-crp and il-6 predict disease severity and mortality in severe community-acquired pneumonia: A propensity score matching study.
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to evaluate the involvementof serum inflammatory markers- N-terminal pro-brainnatriuretic peptide (NT-proBNP), hypersensitive-C reactiveprotein (hs-CRP), and interleukin-6 (IL-6) - in the pathological progression of severe community-acquired pneumonia (SCAP), examine their association with computedtomography (CT) scores, and assess their combined utilityfor diagnosis and outcome prediction. Methods: We performed a propensity score-matched retrospective cohort study involving 164 SCAP patients(research group) and 164 age- and sex-matched healthycontrols (control group) enrolled between March 2024 andJanuary 2025. Serum NT-proBNP hs-CRP and IL-6 concentrations were quantified by enzyme-linked immunosorbent assay (ELISA), while chest computed tomography(CT) manifestations were evaluated using the AcuteExacerbation of Idiopathic Pulmonary Fibrosis (AE-IPF)scoring system. Comparative analyses of inflammatorymarkers and CT imaging findings were conducted, withsubsequent correlation studies, receiver operating characteristic (ROC) curve analysis, and multivariate regressionmodeling to determine their relationship with in-hospitalmortality. Results: Following propensity score matching, demographic characteristics were well-balanced between groups (standardized mean differences <0.1). SCAP patientsdemonstrated significantly elevated serum levels of NTproBNP hs-CRP and IL-6 (P< 0.01), along with higher CTscores than controls. Strong positive correlations wereobserved between inflammatory marker concentrationsand CT scores (P< 0.01). The combined model outperformed individual biomarkers or CT alone in diagnosingSCAP (AUC 0.934, 95%CI 0.910 -0.959; P< 0.001) andpredicting mortality (AUC 0.839, 95%CI 0.759-0.919;P< 0.001). Multivariate analysis identified the elevation ofthese biomarkers as independent predictors of mortality inSCAP patients (P< 0.01). Conclusions: NT-proBNP hs-CRP and IL-6 play pivotal rolesin promoting SCAP progression by driving inflammatorycascades and pulmonary tissue injury. The integratedassessment of these biomarkers with CT scoring significantly improves disease monitoring and prognostic assessment accuracy, potentially guiding individualized antiinflammatory interventions in SCAP management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.